Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Angela Dispenzieri, Steven R. Zeldenrust et al.|Blood|2017Cited by 340
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, Shaji Kumar, Angela Dispenzieri et al.|Blood Cancer Journal|2018Cited by 288
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Shaji Kumar, Angela Dispenzieri et al.|Blood Advances|2022Cited by 26
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myelomaUtkarsh Goel, Shaji Kumar, Angela Dispenzieri et al.|Blood Cancer Journal|2023Cited by 16
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Shaji Kumar, Angela Dispenzieri et al.|Blood Advances|2023Cited by 16